Interview with Synact Pharma about the changes in the company
Biotech company Synact Pharma visited BioStock’s studio to talk about changes in the management and board. With upcoming phase II data during the autumn 2023, the company will focus more on business development. As a consequence, the current chairman Torbjørn Bjerke takes over as CEO when Jeppe Øvlesen steps down at the annual general meeting in May.
See the interview with the outgoing CEO Jeppe Øvlesen, new CEO Torbjørn Bjerke och CSO Thomas Jonassen here:The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.